Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 11fludarabine phosphate 10Rituximab 6Peripheral Blood Stem Cell Transplantation 6Cytarabine 6fludarabine 5Vincristine 4Radiotherapy 4Etoposide 4Whole-Body Irradiation 3Tacrolimus 3Mycophenolic Acid 3Methotrexate 3Filgrastim 3tisagenlecleucel 2blinatumomab 2Vorinostat 2Prednisone 2Pentetic Acid 2Methylprednisolone 2Melphalan 2Drug Therapy 2Doxorubicin 2Cord Blood Stem Cell Transplantation 2Carmustine 2CT-P10 2Busulfan 2Bortezomib 2Biopsy 2Asparaginase 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Burkitt Lymphoma × gallium citrate × Clear all
NCT02776891 2019-10-10

A Feasibility Study of Gallium-68 Citrate PET to Detect Aberrant MYC Proto-Oncogene, BHLH Transcription Factor (MYC) Protein Expression in Diffuse Large B-Cell Lymphoma

University of California, San Francisco

Phase 2 Withdrawn
Lymphoid

Burkitt Lymphoma, Lymphoma, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡